Regulatory press release5/24/2025, 10:40 AMLipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis
Press release5/19/2025, 6:30 AMLipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2
Press release1/21/2025, 7:00 AMLipidor announces half of patients enrolled in ongoing Phase III study
Press release11/20/2024, 7:00 AMLipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"
Press release9/24/2024, 4:30 PMLipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis
Press release8/20/2024, 11:50 AMLipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan
Regulatory press release7/1/2024, 6:15 AMLipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue
Regulatory press release6/25/2024, 7:57 PMLipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants
Regulatory press release6/7/2024, 6:30 AMLast day of trading in unit rights in Lipidor's rights issue
Regulatory press release6/5/2024, 8:00 AMBulletin from the Annual General Meeting of Lipidor AB (publ)
Regulatory press release5/29/2024, 6:00 AMToday the subscription period in Lipidor's rights issue begins